Home / Market News / $STRO

$STRO news and market catalysts

The 7 most recent market catalysts affecting $STRO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 3 high impact 0 bullish 6 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Neutral Impact 65
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Sutro Biopharma (STRO) released its Q3 2026 financial results, showing a slight revenue dip but a substantial reduction in operating expenses, which is a positive for cash manageme…
Nov 7, 2026 Corporate Catalyst Bearish Impact 65
Merck Discontinues Development of Sutro Biopharma-Partnered IL-2 Agonist MK-1484
Merck has decided to discontinue the development of MK-1484, an IL-2 agonist being developed with Sutro Biopharma, due to 'routine pipeline prioritization.' This is a significant e…
Aug 13, 2026 Corporate Catalyst Bearish Impact 55
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34
Citizens analyst Reni J. Benjamin maintained a 'Market Outperform' rating on Sutro Biopharma (STRO), signaling continued confidence in the company's fundamentals and future perform…
Aug 13, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
This 8-K filing discloses that Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating and maintained a $60 price target for Sutro Biopharma (STRO). This action si…
Aug 12, 2026 Corporate Catalyst Bearish Impact 85
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma's stock is experiencing a significant downturn following its update on the STRO-004 Phase 1 study. While the company highlighted early clinical activity and favorab…
Aug 12, 2026 Corporate Catalyst Bearish Impact 85
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Sutro Biopharma. Worse-than-expected financial results often lead to immediate stock price depreciation as investors a…
Aug 12, 2026 Corporate Catalyst Bearish Impact 92
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
Sutro Biopharma's Q2 earnings report revealed a loss per share of $(2.33), missing analyst estimates by 6.39%, and sales of $9.839 million, missing estimates by 24.60%. This repres…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.